सामग्री पर जाएँ

दवाओं की अंतःक्रिया

Risankizumab + Upadacitinib

गंभीरता: गंभीर

Risankizumab and Upadacitinib: major interaction.

अंतिम अपडेट

केवल स्वास्थ्य पेशेवरों के लिए — मात्र संदर्भ हेतु। यह पृष्ठ संक्षिप्त सारांश है, चिकित्सकीय सलाह नहीं है और आधिकारिक लेबल या नैदानिक निर्णय का विकल्प नहीं है। दवा लिखने या देने से पहले हमेशा जाँच करें।

इस पृष्ठ की नैदानिक सामग्री केवल अंग्रेज़ी में उपलब्ध है।

सारांश

Risankizumab blocks IL-23 and upadacitinib inhibits JAK signaling. They are sometimes considered together in inflammatory bowel disease, but combined immunosuppression may increase infection risk and data on safety are limited.

इस इंटरैक्शन का सरल भाषा में अर्थ

Risankizumab and Upadacitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Risankizumab belongs to Miscellaneous; Upadacitinib belongs to Musculoskeletal.

साक्ष्य स्तर: Low

ऐसा क्यों होता है

Additive immunosuppression through IL-23 blockade and JAK inhibition.

क्या करें

Avoid routine combination; if used, screen for tuberculosis and hepatitis beforehand and monitor for infections.

फार्मासिस्ट से क्या पूछें

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ सदस्यों के लिए

पूरा पेज खोलें

Risankizumab और Upadacitinib की पूरी प्रबंधन सलाह, अतिरिक्त नोट्स, साक्ष्य का विवरण और पूरे पर्चे का इंटरैक्शन चेकर खोलने के लिए खाता बनाएँ और Pro+ ट्रायल शुरू करें।

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

वेब पर Pro+ को 7 दिन मुफ़्त आज़माएँ। कार्ड की ज़रूरत नहीं।

अक्सर पूछे जाने वाले प्रश्न

Can I take Risankizumab with Upadacitinib?

MediHelp rates the interaction as major. Risankizumab and Upadacitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Risankizumab blocks IL-23 and upadacitinib inhibits JAK signaling. They are sometimes considered together in inflammatory bowel disease, but combined immunosuppression may increase infection risk and data on safety are limited.

How serious is the interaction between Risankizumab and Upadacitinib?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid routine combination; if used, screen for tuberculosis and hepatitis beforehand and monitor for infections.

What other medicines interact with Upadacitinib?

MediHelp also lists interactions of Upadacitinib with, for example, Abrocitinib, Adenovirus types 4 and 7 live, Baricitinib. The full list is on the Upadacitinib page.

MediHelp ऐप में पूर्ण मोनोग्राफ़, खुराक और इंटरैक्शन चेकर

MediHelp ऐप में पूरा संदर्भ खोलें, कई दवाओं की अंतःक्रियाएँ जाँचें और खुराक टूल इस्तेमाल करें।

A–Z ब्राउज़ करें · दवाओं की अंतःक्रिया

ऐप पाएँ साइन इन